Inflammation, Immunology and Immunotherapeutics

Donald Buchsbaum, Ph.D. – Program Co-Leader

Casey Weaver, M.D. – Program Co-Leader


The Inflammation, Immunology and Immunotherapeutics Program has been a component of the UAB Comprehensive Cancer Center since its inception.  It currently has 32 primary faculty members from eight departments, and the program has $11 million in annual direct grant support including $2.4 million from the National Cancer Institute, $4.6 million from the National Institutes of Health, $1.3 million from other peer-reviewed awards, and $2.7 million in non-peer-reviewed support.

The program has three major areas of emphasis:  (1) development of targeted immunotherapy utilizing antibody specificity to deliver apoptotic stimuli, drugs, or radioactive isotopes to tumors in animal models and human cancer; (2) development of immunization strategies to generate specific immune responses to tumor or tumor inciting agents (tumor vaccines); and (3) to explore basic immunobiology research to translate into immunodiagnostic and immunotherapeutic studies. The program has major collaborations with the Experimental Therapeutics, Cancer Cell Biology, Chemoprevention, and Neuro-Oncology Programs including individual projects in the Breast Cancer, Cervical Cancer, Pancreatic Cancer, and Brain Tumor Specialized Program of Research Excellence grants.

Program Members

Contact Information

Co-Leader: Donald Buchsbaum, Ph.D.
Phone: (205) 934-7077

Co-Leader: Casey Weaver, M.D.
Phone: (205) 975-5537

Leave a Reply